Marker Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- 8
- Market Cap
- -
- Introduction
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.
Safety of MT-401-OTS in Patients with Relapsed AML or MDS
- Conditions
- MDSAcute Myeloid Leukemia, in Relapse
- Interventions
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Marker Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06552416
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
- Conditions
- Pancreas Cancer
- Interventions
- Biological: MT-601
- First Posted Date
- 2024-08-12
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Marker Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06549751
Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
- Conditions
- Hodgkin LymphomaHodgkin's Lymphoma, Relapsed, AdultNon Hodgkin LymphomaNon-Hodgkin Lymphoma, AdultNon-Hodgkin Lymphoma, RefractoryNon-Hodgkin Lymphoma, RelapsedHodgkin Lymphoma, Adult
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Marker Therapeutics, Inc.
- Target Recruit Count
- 79
- Registration Number
- NCT05798897
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Cornell, New York, New York, United States
🇺🇸Colorado Blood Cancer Institute (Sarah Cannon), Denver, Colorado, United States
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Marker Therapeutics, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT04511130
- Locations
- 🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Mayo Clinical Cancer Center-Florida, Jacksonville, Florida, United States
Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
- Conditions
- Platinum Sensitive Ovarian CancerOvarian Cancer
- Interventions
- Drug: Adjuvant (GM-CSF) AloneBiological: FRα peptide plus Adjuvant (GM-CSF)
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2022-12-15
- Lead Sponsor
- Marker Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT02978222
- Locations
- 🇺🇸
The Stamford Hospital/Bennett Cancer Center, Stamford, Connecticut, United States
🇺🇸Research Partners, Jackson, Mississippi, United States
🇺🇸Mayo Clinic Cancer Center, Phoenix, Arizona, United States
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2021-07-19
- Lead Sponsor
- Marker Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT02593227
- Locations
- 🇺🇸
Mount Sinai Hospital, New York, New York, United States
🇺🇸The Valley Hospital, Paramus, New Jersey, United States
🇺🇸University of Maryland - Greenebaum Cancer Center, Baltimore, Maryland, United States